A Study to Compare the Pharmacokinetics (PK) of Depemokimab When Delivered With a Safety Syringe Device (SSD) or an Autoinjector in Healthy Adult Participants

NCT05602025 ↗

Phase 1 Completed 140 enrolled GlaxoSmithKline PPD Development, LP · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

This study will compare the pharmacokinetics, safety, tolerability, and immunogenicity of Depemokimab administered via a SSD or autoinjector in healthy participants.

Timeline

Start: 2022-12-13
Primary completion: 2023-10-23
Completion: 2023-10-23

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Depemokimab	Protein / enzyme biologic	100 mg	Subcutaneous

A Study to Compare the Pharmacokinetics (PK) of Depemokimab When Delivered With a Safety Syringe Device (SSD) or an Autoinjector in Healthy Adult Participants

Summary

Timeline

Drugs

Indications